Abstract
Post-transplant (post-Tx) kidney cancer has become the second-highest cause of death in kidney recipients. Late diagnosis and treatment are the main reasons for high mortality. Further research into early diagnosis and potential treatment is therefore required. In this current study, through genome-wide RNA-Seq profile analysis of post-Tx malignant blood samples and post-Tx non-malignant control blood samples (CTRL-Tx), we found Rap GTPase Interactor (RADIL) and Aprataxin (APTX) to be the most meaningful markers for cancer diagnosis. Receiver operating characteristic (ROC) curve analysis showed that the area under the curve (AUC) of the RADIL-APTX signature model was 0.92 (P < 0.0001). Similarly, the AUC of RADIL alone was 0.91 (P < 0.0001) and that of APTX was 0.81 (P = 0.001). Additionally, using a semi-supervised method, we found that RADIL alone could better predict malignancies in kidney transplantation recipients than APTX alone. Kaplan-Meier analysis indicated that RADIL was expressed significantly higher in the early stages (I and II) of kidney, liver, stomach, and pancreatic cancer, suggesting the potential use of RADIL in early diagnosis. Multivariable Cox regression analysis found that RADIL together with other factors (including age, stage III, stage IV and CD8+ T cells) play a key role in kidney cancer development. Among those factors, RADIL could promote kidney cancer development (HR > 1, P < 0.05) while CD8+ T cells could inhibit kidney cancer development (HR < 1, P < 0.05). RADIL may be a new immunotherapy target for kidney cancer post kidney transplantation.
Highlights
As the optimal treatment for end-stage renal disease (ESRD), renal transplantation can improve the quality of life and overall survival (OS) significantly compared to traditional treatments in ESRD patients [1, 2]
Establishment of the Gene Prognostic Model. Among those top 10 genes, Rap GTPase Interactor (RADIL) and APTX were identified as the Differentially expressed analysis (DEGs) between the malign group and non-malign group
According to receiver operating characteristic (ROC) curves of RADIL and APTX, we found RADIL has a similar area under the curve (AUC) (AUC = 0.91) value with that of 2-gene signature (AUC = 0.92)
Summary
As the optimal treatment for end-stage renal disease (ESRD), renal transplantation can improve the quality of life and overall survival (OS) significantly compared to traditional treatments in ESRD patients [1, 2]. Identifying new markers for early detection and treatment remain essential to improving the survival of recipients and kidney graft. Various immune signaling cascades are altered due to post-Tx cancer development. Many other factors such as age, race, and drug sensitivity affect the efficacy of current therapies. These shortcomings in cancer prognosis and therapy necessitate further study of the broader mechanisms of cancer immunity
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
